$EQ
Equillium, Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019031483 Filed on August 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.140M $2.190M $1.710M
YoY Change 114.0% 968.75%
% of Gross Profit
Research & Development $4.182M $4.250M $2.520M
YoY Change 242.79% 687.04% 425.0%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $10.00K
YoY Change
% of Gross Profit
Operating Expenses $6.324M $6.439M $4.228M
YoY Change 184.1% 472.36% -760.83%
Operating Profit -$6.324M -$6.439M
YoY Change 184.11% 472.36%
Interest Expense $320.0K $380.0K -$760.0K
YoY Change -111.9% 61.7%
% of Operating Profit
Other Income/Expense, Net $310.0K $370.0K
YoY Change -111.52% -157.81%
Pretax Income -$6.010M -$6.070M -$4.990M
YoY Change 22.15% 349.55%
Income Tax
% Of Pretax Income
Net Earnings -$6.014M -$6.069M -$4.992M
YoY Change 22.31% 243.85% 351.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$345.8K -$349.3K -$307.1K
COMMON SHARES
Basic Shares Outstanding 17.38M 17.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.20M $56.94M $65.91M
YoY Change 1144.0% 762.79% 827.89%
Cash & Equivalents $27.66M $22.66M $28.51M
Short-Term Investments $34.60M $34.28M $37.41M
Other Short-Term Assets $700.0K $900.0K $1.200M
YoY Change 600.0% 800.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $62.90M $57.80M $67.10M
YoY Change 1143.01% 762.63% 838.53%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $77.00K $64.00K
YoY Change 213.61% 2981.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $15.00K
YoY Change -100.0%
Total Long-Term Assets $100.0K $92.00K $64.00K
YoY Change -92.65% 2981.37%
TOTAL ASSETS
Total Short-Term Assets $62.90M $57.80M $67.10M
Total Long-Term Assets $100.0K $92.00K $64.00K
Total Assets $63.00M $57.89M $67.16M
YoY Change 881.07% 764.0% 839.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $1.974M $1.119M
YoY Change 119.47% 558.0% 359.09%
Accrued Expenses $1.600M $1.688M $909.0K
YoY Change 10.38% 181.33% 179.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.300M $3.662M $2.028M
YoY Change 60.46% 306.89% 256.53%
LONG-TERM LIABILITIES
Long-Term Debt $9.616M $0.00 $0.00
YoY Change -17.1% -100.0% -100.0%
Other Long-Term Liabilities $146.0K $200.0K $200.0K
YoY Change -1.83% -77.78% -75.0%
Total Long-Term Liabilities $9.762M $163.0K $200.0K
YoY Change 6463.84% -98.57% -97.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.300M $3.662M $2.028M
Total Long-Term Liabilities $9.762M $163.0K $200.0K
Total Liabilities $14.04M $3.825M $2.228M
YoY Change -16.45% -68.9% -76.31%
SHAREHOLDERS EQUITY
Retained Earnings -$33.55M -$27.53M -$15.51M
YoY Change 585.8%
Common Stock $82.42M $81.51M $80.44M
YoY Change 58071.24% 821659.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.96M $54.06M $64.94M
YoY Change
Total Liabilities & Shareholders Equity $63.00M $57.89M $67.16M
YoY Change 884.3% 764.0% 839.15%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q4
OPERATING ACTIVITIES
Net Income -$6.014M -$6.069M -$4.992M
YoY Change 22.31% 243.85% 351.21%
Depreciation, Depletion And Amortization $10.00K $0.00 $10.00K
YoY Change
Cash From Operating Activities -$4.700M -$4.760M -$3.830M
YoY Change 186.59% 131.07% 882.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$50.00K $0.00
YoY Change -100.0% 150.0%
Acquisitions
YoY Change
Other Investing Activities -$230.0K $6.090M -$37.40M
YoY Change
Cash From Investing Activities -$230.0K $6.040M -$37.40M
YoY Change 2200.0% -30300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.940M 0.000 64.77M
YoY Change -100.0% 856.72%
NET CHANGE
Cash From Operating Activities -4.700M -4.760M -3.830M
Cash From Investing Activities -230.0K 6.040M -37.40M
Cash From Financing Activities 9.940M 0.000 64.77M
Net Change In Cash 5.010M 1.280M 23.54M
YoY Change -403.64% -366.67% 268.97%
FREE CASH FLOW
Cash From Operating Activities -$4.700M -$4.760M -$3.830M
Capital Expenditures $0.00 -$50.00K $0.00
Free Cash Flow -$4.700M -$4.710M -$3.830M
YoY Change 188.34% 130.88% 882.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Type
DocumentType
10-Q
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
38000
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17376236
dei Entity File Number
EntityFileNumber
001-38692
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
821554746
dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
412-5302
dei Trading Symbol
TradingSymbol
EQ
dei Entity Registrant Name
EntityRegistrantName
EQUILLIUM, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001746466
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
us-gaap Operating Income Loss
OperatingIncomeLoss
-12787000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2162000
CY2018Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
619000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
375000
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
19000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5950000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
59494000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
19000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
581000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
77000
us-gaap Investment Income Interest
InvestmentIncomeInterest
773000
us-gaap Investment Income Interest
InvestmentIncomeInterest
30000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1119000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22661000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28508000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34283000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2019Q2 us-gaap Assets
Assets
57888000
CY2018Q4 us-gaap Assets
Assets
67163000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1974000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1180000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6069000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1765000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1000
us-gaap Profit Loss
ProfitLoss
-12019000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
11000
us-gaap Share Based Compensation
ShareBasedCompensation
1027000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1688000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37405000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
852000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1186000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
57796000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
67099000
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2018Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
8000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3662000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000
us-gaap Operating Expenses
OperatingExpenses
12787000
us-gaap Operating Expenses
OperatingExpenses
2162000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6439000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1125000
us-gaap Interest Expense Debt
InterestExpenseDebt
1108000
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
25000
CY2019Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
163000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
200000
CY2019Q2 us-gaap Liabilities
Liabilities
3825000
CY2018Q4 us-gaap Liabilities
Liabilities
2228000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
81506000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
80441000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
87000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27531000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15512000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
54063000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
64935000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57888000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67163000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17376236
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17376236
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17376236
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17376236
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4250000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
540000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8009000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1203000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2189000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
585000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4778000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
959000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6439000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
1125000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2018Q2 eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
46000
eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
102000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-640000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
768000
us-gaap Net Income Loss
NetIncomeLoss
-12019000
us-gaap Net Income Loss
NetIncomeLoss
-3342000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
39000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
83000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5847000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-478000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28508000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7104000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22661000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
82000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6031000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1765000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11937000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3342000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10715461
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10711788
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2252000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1577000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-3829000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-5593000
us-gaap Profit Loss
ProfitLoss
-3342000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
us-gaap Share Based Compensation
ShareBasedCompensation
1000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1108000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
241000
us-gaap Other Noncash Expense
OtherNoncashExpense
12000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-318000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
890000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
103000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
782000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9220000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2058000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
25630000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
29075000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3389000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1599000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1602000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6626000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company&#8217;s condensed consolidated financial statements relate to clinical trial accruals and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3169450
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2126877
CY2017Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
15000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2019Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56900000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1203483
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1203483
CY2019Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
34283000
CY2018Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
37405000
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34195000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
88000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37400000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
667000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
560000
CY2019Q2 eq Accrued Clinical Studies
AccruedClinicalStudies
853000
CY2018Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
245000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
153000
CY2019Q2 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
15000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
581000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1027000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000

Files In Submission

Name View Source Status
0001564590-19-031483-index-headers.html Edgar Link pending
0001564590-19-031483-index.html Edgar Link pending
0001564590-19-031483.txt Edgar Link pending
0001564590-19-031483-xbrl.zip Edgar Link pending
eq-10q_20190630.htm Edgar Link pending
eq-20190630.xml Edgar Link completed
eq-20190630.xsd Edgar Link pending
eq-20190630_cal.xml Edgar Link unprocessable
eq-20190630_def.xml Edgar Link unprocessable
eq-20190630_lab.xml Edgar Link unprocessable
eq-20190630_pre.xml Edgar Link unprocessable
eq-ex101_162.htm Edgar Link pending
eq-ex311_7.htm Edgar Link pending
eq-ex312_8.htm Edgar Link pending
eq-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending